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Introduction: Few studies have explored the association of COPD, based on GOLD definition,
with heart diseases. The relationship between restrictive lung function impairment and heart
diseases is still poorly studied on a population level.
Objectives: To explore the association of COPD and restrictive lung function impairment,
respectively, with heart diseases in the general population.
Design: This is a cross-sectional study of 642 randomly selected 22- to 72-year-old subjects in
northern Sweden. COPD was defined according to GOLD. Restrictive lung function was defined
as pre-bronchodilator FVC <80% of predicted value and FEV1/FVC 0.7.
Results: The prevalence of ischemic heart disease was 4% in subjects with normal spirometry,
13% in subjects with COPD, and 21% in those with restrictive lung function. The prevalence of
heart diseases increased with COPD severity. On the other hand, the prevalence of COPD was
particularly high in the group reporting myocardial infarction. In subjects reporting different
heart diseases, the prevalence of restrictive lung function was high. In multivariate analyses
including age, sex, smoking habits, family history of obstructive airway disease, body mass
index, and socio-economic status as independent variables, COPD was associated with
ischemic heart disease (odds ratio [OR] 2.61; 95% confidence interval [CI] 1.12e6.08) and
ischemic heart disease with COPD (OR 2.40; 95% CI 1.03e5.61).t of Internal Medicine, The Central County Hospital of Halmstad, Lasaretssva¨gen, 30185 Halmstad,
n@telia.com (B. Eriksson), anne.lindberg@nll.se (A. Lindberg), hana.x.muellerova@gsk.com
(E. Ro¨nmark), bo.lundback@gu.se (B. Lundba¨ck).
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Heart disease, COPD and restrictive lung function 99Conclusion: The study shows a strong association between COPD and cardiovascular diseases
and indicates a strong association between restrictive lung function and heart diseases. Both
obstructive and restrictive lung function impairments were common among subjects with heart
diseases and vice versa.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) and heart
diseases are major causes of morbidity, mortality, and
costs1e4 and share lifestyle-related risk factors.5e9 Among
the elderly, about half of smokers continuing smoking
sooner or later develop COPD.10 Although well recognized,
an association between smoking and ischemic heart disease
is not of similar magnitude.5 Several previous studies11e18
have provided evidence for an association between COPD
and cardiovascular diseases, but most of these studies did
not use the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) or other modern criteria or were based on
selected populations.19 Only few recent studies have
explored the associations based on the GOLD definition of
COPD, and the relationship between restrictive lung func-
tion impairment and heart diseases is still poorly studied on
a population level.15,16
Dynamic spirometry is a handy and accessible tool for
evaluating the presence of COPD. Dynamic spirometry can
also detect a pathological lung function among subjects
that do not fulfill criteria for COPD.
The aim of the present study was to explore the asso-
ciation of heart diseases and hypertension with COPD and
with restrictive lung function impairment, respectively, by
using a database derived from large-scale population
studies.4,10,20,21 A further aim was to study the risk factors
for COPD, restrictive lung function impairment, and
ischemic heart disease in the same population. COPD is still
underdiagnosed in the general population,10,20e23 and
hence, there is a need for population-based studies of the
associations of these conditions.Materials and methods
Study sample
A postal questionnaire survey was performed in 1992 in the
province of Norrbotten, Sweden, as a part of the Obstruc-
tive Lung Disease in Northern Sweden (OLIN) Studies. The
study sample was randomly selected from all 20- to 69-
year-old subjects, and 4851 subjects (85%) participated.24
In 1994e1995, a random sample of the responders,
comprising 970 subjects, was invited for clinical examina-
tions including structured interviews and lung function
tests.21 This visit was used for the current analysis.
Complete information on diseases, symptoms, lung func-
tion, and demographics was present in 642 subjects. The
representativeness of the study was evaluated by
comparing the questionnaire responses of the 642 subjects
with the prevalence of symptoms, diseases, currentsmokers and other possible determinants of disease among
all 4851 questionnaire study participants. The difference in
prevalence was <2%-units and not significant for the large
majority of questions, why the representativeness was
considered very good.
The ethical committee at the University Hospital of
Umea˚ approved the study.
Methods
Specially trained nurses performed the interviews and the
lung function tests. The questionnaire was validated and
has been used in Sweden and other countries.21,25 It
includes questions about respiratory symptoms and
diseases, cardiovascular diseases, other comorbid condi-
tions, use of medicines, smoking habits, occupation, and
socioeconomic status. Data on family history of obstructive
airway diseases were added from the postal survey. For
spirometry, the ATS guidelines26 were followed, except that
the subjects were standing during the examinations, and
slow vital capacity (SVC) measurements were performed in
addition to forced vital capacity (FVC). Vital capacity (VC)
was defined as the highest of SVC or FVC. In subjects with
either a ratio of FEV1/VC of less than 0.7 or FEV1 of less
than 90% of predicted value a reversibility test with 0.4 mg
salbutamol was used.
Definitions
COPD and its severity stages were defined according to the
GOLD criteria6,27: Subjects were considered as suffering
from COPD if their FEV1/VC ratio was less than 0.7. Subjects
without COPD were divided into “normal” and “restrictive
lung function” groups, the latter being defined as
pre-bronchodilator FVC <80% of predicted value and
FEV1/FVC 0.7.
The highest values of FEV1 and of FVC or SVC, before or
after the reversibility test, were used for the FEV1/VC ratio
calculations and for grading of the severity of COPD.28
GOLD stages 3 and 4 were combined to increase the size
of this stratum. Swedish reference values reported by
Berglund were applied.29 These conform well to the
middle-aged and elderly adult symptom-free population in
Norrbotten.30
Body mass index (BMI), defined as weight divided by
square of height in meters, was used as a continuous vari-
able. Ischemic heart disease (IHD) was defined as an
interview report of a history of myocardial infarction,
angina pectoris, or both, as these conditions are both
outcomes of coronary heart disease. The classification
of socioeconomic status was based on occupation and
followed the definitions of Statistics Sweden.31
Figure 1 Proportional Venn-diagram of the proportions of
ever-smokers among subjects with COPD, normal spirometry
and with a restrictive lung function and the overlap between
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In univariate analyses, the chi-square test was used for
categorical variables, and the t-test was used for test the
difference of means in continuous variables. Multivariate
logistic regression was used to test determinants of COPD,
restrictive lung function, or IHD. The independent variables
that were significantly associated with the studied condi-
tions were included in the multivariate analyses. The
following covariates were thus used: sex, age, smoking
habits, family history of obstructive airway disease (i.e.,
chronic bronchitis, emphysema, or asthma among parents
or siblings), socio-economic status, and BMI. Age was
dichotomized, with 50 years as cut-off based on the mean
of the population, which is close to identical to the median.
For univariate analyses BMI was divided into two groups
with BMI 25 and BMI >25, based on the mean. Multinomial
logistic regression was performed in order to model risk
factors for the two spirometric patterns, COPD and
restrictive lung function, at the same time, and these
results have been included in an Online Supplement. All
analyses were made using the Statistical Package for Social
Science (SPSS) software version 17.0.the groups. AZ Ever-smokers, BZ COPD, CZ Ischemic heart
disease, D Z Restrictive lung function; A þ B Z Ever-smokers
with COPD, A þ C Z Ever-smokers with IHD, A þ D Z Ever-
smokers with restrictive lung function.Results
Baseline characteristics
The mean age in the total cohort was 49 years with a range
of 23e72 y. COPD based on spirometry was found in 14% of
subjects, of which 8% fulfilled the criteria of COPD GOLD
stage 2. Only 19 subjects (3%) fulfilled the criteria for
restrictive lung function impairment. However, additionally
five subjects had a pre-bronchodilator FVC <80% of pre-
dicted and FEV1/FVC >0.7, but were volume responders
and normalized their FVC and fulfilled the criteria for
COPD. Fig. 1 shows proportions and associations of ever
smokers without or with COPD, restrictive lung function and
ischemic heart disease. Mean age was 54 years among
subjects having COPD, 58 years among restrictive lung
function subjects, and 48 years among those with normal
spirometry (Table 1).
Smoking habits (ever smokers) were significantly
different between COPD subjects (80%) and those with
normal (51%) or restrictive lung function (53%) (p < 0.001).
The proportion of ever smokers among subjects with COPD
without ischemic heart disease (80%) and with ischemic
heart disease (83%) was similar. Among subjects having
ischemic heart disease but not COPD, 56% were or had been
smokers.
COPD and heart diseases
Myocardial infarction, angina pectoris, ischemic heart
disease, and hypertension or any heart disease or relevant
medications were substantially more common in COPD
compared with subjects with normal spirometry (Table 1).
In detail, myocardial infarction was reported by 7% of COPD
subjects but only by 2% of those with a normal spirometry
(p < 0.005). Similarly, ischemic heart disease was reportedby 13% of subjects with COPD versus 4% by subjects with
normal spirometry. Hypertension was reported by 29% of
subjects with COPD versus 16% among those with a normal
spirometry. The proportion of the combined parameter of
any heart disease, hypertension, and medication for heart
diseases or hypertension was almost twice as high in
subjects with COPD compared with those not having COPD.
Prevalence of concomitant cardiovascular diseases
increased with increasing disease severity of COPD (Fig. 2).
Heart failure and arrhythmia did not differ significantly
between those with or without COPD (Table 1).
COPD was detected in 35% of subjects reporting
myocardial infarction, in 26% of subjects with angina pec-
toris, and in 22% in the group reporting hypertension. The
prevalence of COPD among subjects without the corre-
sponding cardiovascular conditions was significantly lower
and varied from 12% to 14% (Table 2).
Restrictive lung function and heart disease
Heart diseases were about three to six times more common
among subjects with restrictive lung function impairment
compared with subjects with normal spirometry (Table 1).
The proportions of subjects with heart diseases, hyper-
tension, and medication for heart diseases or hypertension
in restrictive subjects were similar to that in subjects
having COPD of stage 3 and 4 (Fig. 1), and 39% used medi-
cines for heart disease or hypertension, while 58% reported
any heart disease or hypertension or any medication for
heart disease. Restrictive lung function impairment was
significantly more common in subjects with ischemic heart
disease, heart failure, arrhythmia, or other heart diseases
(Table 3).
Table 1 Characteristics of the study subjects with a valid spirometry.
Normal COPD Restrictive Total
Men, N Z (%) 260 (49.2) 49 (53.8) 10 (52.6) 321 (50.0)
Women, N Z (%) 270 (50.) 42 (46.2) 9 (47.4) 321 (50.0)
Total, N Z (%) 533 (82.9) 92 (14.3) 18 (32.8) 642
Mean age (years) 47.7 54.54 58.0a 49.0
Smoking habits, N Z (%)
Never smoker 262 (49.3) 18 (19.8)a 9 (47.4) 289 (45.1)
Ex-smoker 146 (27.5) 32 (35.2)a 4 (21.1) 182 (28.4)
Current smoker 123 (23.2) 41 (45.1)a 6 (31.6) 170 (26.5)
Reported OLD,b N Z (%) 21 (4.0) 10 (11.0)a 2 (10.5)a 33 (5.1)
Family history of OLD, N Z (%) 142 (26.7) 37 (40.7)a 9 (47.4) 188 (29.3)
BMI e mean (kg m2) 25.6 24.9a 27.6a 25.6
Socioeconomic status, N Z (%)
Professionals and civil servants 164 (30.9) 20 (22.0) 4 (21.1) 188 (29.4)
Manual workers in industry 99 (18.7) 23 (25.3) 5 (26.3) 127 (19.8)
Manual workers in service 152 (28.7) 25 (27.5) 4 (21.1) 181 (28.3)
Nonmanual assist employee 70 (13.2) 14 (15.4) 4 (21.1) 88 (13.8)
Housewives 7 (1.3) 2 (2.2) 1 (5.3) 10 (1.6)
Self-employed, nonprofessional 25 (4.7) 5 (5.5) 1 (5.3) 31 (4.8)
Students 13 (2.5) 2 (2.2) 0 (0) 15 (2.3)
Heart disease, N Z (%)
Myocardial infarction 9 (1.7) 6 (6.6)a 2 (10.5)a 17 (2.7)
Angina pectoris 19 (3.6) 8 (8.8)a 4 (21.1)a 31 (4.8)
Heart failure 4 (0.8) 2 (2.2) 1 (5.3) 7 (1.1)
Arrhythmia or other heart disease 21 (4.0) 3 (3.3) 5 (26.3)a 29 (4.5)
Hypertension 86 (16.2) 26 (28.6)a 6 (31.6) 118 (18.4)
Use of medicinesc 74 (14.2) 23 (26.1)a 7 (38.9)a 104 (16.6)
Any heart disease, hypertension or medicationc 120 (22.6) 36 (39.6)a 11 (57.9)a 167 (26.1)
Ischemic heart diseased 23 (4.3) 12 (13.2)a 4 (21.1)a 39 (6.1)
COPD, N Z (%) 91 (14.2)
Mild COPD 42 (46.2)
Moderate COPD 37 (40.7)
Severe COPD 8 (8.8)
Very severe COPD 4 (4.4)
Difference between groups was tested using t-test for continuous and chi-square test for categorical variables.
a Significant difference from the group with normal spirometry.
b Physicians’ diagnosis of chronic bronchitis or emphysema (OLD).
c Medication for heart disease or hypertension.
d Angina pectoris, history of myocardial infarction, or both.
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heart disease
In multiple logistic regression analysis (Table 4), COPD was
significantly associated with ischemic heart disease (OR
2.61; 95% CI 1.12e6.08), and ischemic heart disease was
significantly associated with COPD (OR 2.40; 95% CI
1.03e5.61). In contrast to the univariate analysis (Online
Supplement), the associations between restrictive lung
function and ischemic heart disease did not reach statis-
tical significance in the multivariate analyses. Both current
and previous smoking was significantly associated with
COPD as was a family history of obstructive airway disease
and a decreased BMI. All socioeconomic classes, except
professionals and executives and self-employed non-
professionals, had increased ORs for ischemic heart
disease; further, increase of BMI also yielded a significantly
increased OR. Older age was the only common risk factorfor COPD, restrictive lung function, and ischemic heart
disease.Discussion
We found a strong association between ischemic heart
disease and impaired lung function. Our study further
showed an increasing prevalence of heart diseases with
increasing COPD severity and also high proportions of heart
diseases among subjects with restrictive lung function.
Our study confirms results from previous studies
including the magnitude of associations between obstruc-
tive disease and heart diseases.16,17,32 However, most
studies were based on populations identified in primary
care, by hospitalizations or by prescription of drugs.33e37 As
about one third of subjects with COPD generally have no
previous diagnosis,10,20e23 such studies do not reflect the
Figure 2 Proportion of subjects with (a) ischemic heart
disease; (b) medication for any heart disease or hypertension;
and (c) any heart disease, hypertension, or medication for
heart disease or hypertension among subjects with normal
spirometry and COPD stratified by disease severity and among
subjects with restrictive lung function. Note: BMI was calcu-
lated as weight in kilograms divided by the square of height in
meter and was treated as a continuous variable.
102 B. Eriksson et al.true distribution of the disease in the society. Only a few
studies have reported associations between heart diseases
and COPD stratified by disease severity, and only rarely
have associations between heart diseases and restrictive
lung function been studied.16,17,32 We did not find any
published population based study where the proportions of
subjects with COPD having heart diseases, and vice versa,
have been presented from the same population.
The association between ischemic heart disease and
COPD remained significant after adjustments for known risk
factors. The association between ischemic heart disease and
restrictive lung function found in the unadjusted analysis did
not reach significance in the multivariate setting, probably
a result of lack of power. However, the study may indicate
a possible causative relationship between heart diseases and
both COPD and restrictive lung function also beyond their
common risk factors. A link with systemic inflammation has
been reported in the etiology of these diseases38; however,
the nature of these associations has to be studied further.Table 2 Proportion (%) of subjects with COPD among subjects w
risk (RR) for COPD by having or not having the cardiovascular con
test.
Cardiovascular condition COPD among
with corresp
condition (%)
Myocardial infarction 35.3
Angina pectoris 25.8
Ischemic heart disease 30.8
Heart failure 28.6
Arrhythmia or any other heart disease 10.3
Hypertension 22.0
Medicines for heart disease or hypertension 22.1
Any heart disease, hypertension, or medicinea 21.6
Any heart disease or hypertension 22.7
a Any medication for heart disease or hypertension.Both current smoking and previous smoking remained
solid risk factors for COPD also after correction for other
known causes. Smoking is a well-established risk factor for
coronary heart disease,5,39e41 although we were not able to
verify this, similar to another recently published report.17
The risk factor pattern for ischemic heart disease is more
diverse and includes diabetes, family history, and
obesity,5,8,42 and our study was not able to control for all
these factors. In a cross-sectional study, it is possible that
subjects insensitive to cigarette smoke, with regard to
coronary injury, prevail (a “healthy survivor” effect); this
can yield a higher proportion of smokers among healthy
subjects, whereas those susceptible to cigarette smoke can
be failing in older subjects. Among those with both
ischemic heart disease and COPD, 80% were ever-smokers
versus 53% among those not having any of the two diseases.
The association with manual workers in the industry
could be explained by occupational exposures to gas, dust,
or fumes.43,44 However, a socio-economic component has
been verified because significant associations were also
found between ischemic heart disease and manual workers
in service and non-manual assistant employees without the
above exposures.8 As expected, a low BMI was associated
with an increased risk for COPD, whereas the opposite was
found for ischemic heart disease.
Restrictive dynamic spirometry may reflect several
underlying disorders such as idiopathic pulmonary fibrosis,
systemic diseases, sarcoidosis, thoracic deformities,
obesity, pregnancy, pleural effusion, neuromuscular
diseases, and pain. Dynamic spirometry has limitations in
identifying restrictive lung diseases,45 however, it can be
used to exclude a restrictive disease when FVC is normal,
and its sensitivity increases when taking into account the
FEV1/FVC ratio.
46,47 When using dynamic spirometry, i.e.
without information of total lung capacity, results sug-
gesting restrictive spirometry must be judged with caution.
Furthermore, some subjects with combined obstructive and
restrictive lung diseases cannot be identified.48 Despite the
limitations and uncertainty by using dynamic spirometry
only, we consider that we have identified a group with
restrictive spirometry among whom heart diseases was
common.ith and without different cardiovascular conditions. Relative
ditions. Statistical difference was tested using the chi-square
subjects
onding
COPD among subjects
without corresponding
condition (%)
R.R. p-value
13.6 2.6 0.011
13.6 1.9 0.057
13.1 2.4 0.002
14.0 2.0 0.27
14.4 0.7 0.54
12.4 1.8 0.007
12.3 1.8 0.008
11.6 1.9 0.001
11.8 1.9 0.001
Table 3 Proportion (%) of subjects with restrictive lung function among subjects with and without different cardiovascular
conditions. Relative risk (RR) for restrictive lung function by having or not having the cardiovascular conditions. Statistical
difference was tested using the chi-square test.
Cardiovascular condition Restrictive lung function
among subjects with
corresponding condition (%)
Restrictive lung function
among subjects without
corresponding condition (%)
R.R. p-value
Myocardial infarction 18.2 3.2 5.7 0.007
Angina pectoris 17.4 2.8 6.2 <0.001
Ischemic heart disease 14.8 2.9 5.1 0.001
Heart failure 20.0 3.3 6.1 0.042
Arrhythmia or any other heart disease 19.2 2.7 7.1 <0.001
Hypertension 6.5 2.8 2.3 0.078
Medicines for heart disease or hypertension 8.6 2.4 3.6 0.004
Any heart disease, hypertension or medicinea 8.4 1.9 4.4 <0.001
Any heart disease or hypertension 8.3 2.3 3.6 0.002
a Any medication for heart disease or hypertension.
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issue of restrictive lung function and heart disease.15e17,32
One study found a significant association between restric-
tive lung function impairment and incident cardiovascular
disease defined as myocardial infarction, stroke, heart
failure, angina, or transient ischemic attacks.16 Signifi-
cantly increased hazard ratios (HRs) for cardiovascular
disease were demonstrated in all COPD severity stages as
well as in the restrictive group,16 results in line with ours. In
another report partly based on the same study population,
a complex definition of cardiovascular disease was used.17
Despite the large cohort size, the odds ratios for baseline
cardiovascular diseases were significant only for GOLDTable 4 Risk factors for COPD, restrictive lung function and isch
Risks expressed as odds ratios (ORs) with 95% confidence interval
COPD R
OR 95% CI O
Sex (male) 1.13 0.64e1.97 1
Age (50 years)a 2.66 1.57e4.49 5
Smoking habits
Never smoker 1.0 1
Ex-smoker 2.60 1.36e4.96 0
Smoker 4.68 2.51e8.71 1
BMI (kg m2)b 0.92 0.86e0.99 1
Family History of OLDc 1.74 1.06e2.86 2
Socioeconomic status
Professionals and executives 1.0 1
Manual workers in industry 1.70 0.84e3.48 1
Manual workers in service 1.23 0.62e2.45 0
Assistant nonmanual employee 1.31 0.59e2.94 1
Self-employed, nonprofessionals 1.25 0.40e3.90 1
Ischemic heart disease 2.40 1.03e5.61 2
Spirometric pattern
Normal spirometry
COPD
Restrictive lung function
a Age is dichotomized into two groups, 21e49 and 50e72 years.
b BMI is treated as a continuous variable.
c OLD Z obstructive lung disease.0 and 2 and for the restrictive group. In the whole cohort,
incident cardiovascular disease was significantly increased
among the COPD severity stages GOLD 0, 2, 3, and 4 and for
the subjects with a restrictive lung function.17 Analyses
of the US NHANES data with respect to restrictive lung
function showed a higher prevalence among subjects with
diabetes. The four referred studies found a prevalence of
restrictive lung function of 6e14%.15e17,23 In contrast, we
identified 3% in a random sample of the general population.
We have found few studies, apart from these four,
revealing prevalence of restrictive lung function. In a study
on Swedish construction workers, using a similar definition,
the prevalence of restrictive lung function was 4%.43 Theemic heart disease analyzed using multiple logistic regression.
s (CIs).
estrictive lung function Ischemic heart disease
R 95% CI OR 95% CI
.31 0.42e4.12 0.99 0.40e2.42
.47 1.43e19.24 9.60 2.84e32.43
.0 1.0
.62 0.14e2.22 1.88 0.78e4.52
.94 0.63e5.96 0.85 0.30e2.41
.08 0.96e1.23 1.14 1.04e1.25
.40 0.90e6.40 1.34 0.62e2.86
.0 1.0
.85 0.43e7.93 5.37 1.48e22.22
.93 0.21e4.01 4.63 1.20e17.76
.97 0.45e8.70 4.59 1.07e19,65
.04 0.10e10.90 1.86 0.18e19.60
.59 0.64e9.99
1.0
2.61 1.12e6.08
2.93 0.78e10.96
104 B. Eriksson et al.skill of the personnel and the cooperation with the subjects
under study is critical when using dynamic spirometry for
detecting restrictive lung function. Our staffs are well
trained and experienced, and the number of persons per-
forming the lung function tests is limited, thus limiting
inter-observer bias. Restrictive lung function is more
common among obese subjects, and the higher prevalence
of restrictive lung function in some studies could reflect
a higher prevalence of obesity. We also consider that the
risk analyses together with the relatively low prevalence of
restrictive lung function indicate that our study might have
been underpowered for assessing a solid risk pattern and
estimate of prevalence of restrictive lung function in the
population.
There are several strengths with the present report. The
study was based on a random sample of adults of the
general population, lung function measurement was used to
define COPD and restrictive lung function, and a validated
structured interview was used to collect demographics and
clinical information. The survey reflects well a clinical
setting where a spirometric investigation allows identifi-
cation of the subjects with a normal spirometry, COPD, or
restrictive lung function impairment. A limitation of our
study is the lack of objective measurements verifying heart
diseases. Regarding the medical history of heart diseases
and hypertension, there is a good agreement between
the self-report of the disease and objectively assessed
occurrence of hypertension, angina pectoris, myocardial
infarction, and stroke49,50 but not of heart failure.51
Furthermore, our estimates of prevalence of heart
failure, ischemic heart diseases, BMI, and hypertension
conform well to other Swedish results on prevalence of
these diseases.52,53 A limitation when calculating risks is
the cross-sectional design. Thus, associations may reflect
cause or consequence or even parallel phenomena and
conclusions regarding causality cannot be made. Selection
bias was minimized by the random sampling and a relatively
high participation rate.
Our data show a strong association between COPD and
heart diseases and hypertension in a random sample of
a Swedish general population and demonstrate a relation-
ship between restrictive lung function and heart diseases,
the latter however not significant in the multivariate
analyses. Lung function impairments, both obstructive and
restrictive, were common among subjects with heart
diseases, and similarly, heart diseases were common in
subjects with lung impairment. Spirometry is widely used in
primary as well as secondary care. Clinical implications of
these findings include a suggestion for physicians to take
into consideration cardiovascular diseases in subjects with
a pathological lung-function of both COPD and of a restric-
tive pattern, and to evaluate a possibility of COPD or
restrictive lung function impairment among subjects with
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